Clinical trial
Study Evaluating Sirolimus in Kidney Transplant Recipients in India
NCT00195481 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00195481 |
|---|---|
| Title | Study Evaluating Sirolimus in Kidney Transplant Recipients in India |
| Official title | A Post Marketing Surveillance Looking at Safety of Rapamune (Sirolimus) in Indian Population Undergoing de Novo Renal Transplantation. |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Kidney Failure, Graft vs Host Disease |
| Intervention type | Drug |
| Interventions | Rapamune |
| Enrollment | 100 |
| Start date | Apr 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Dec 28, 2007 |
| Countries | India |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: